

November 02, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Un-audited Financial Results for the Quarter & Half Year ended September 30, 2023

Ref: Compliances under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/ Madam,

Please take note that the Board of Directors in their meeting held today i.e. November 02, 2023 inter-alia considered and approved the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter & Half Year ended September 30, 2023.

A signed copy of the above Financial Results along with Limited Review Report issued thereon by the Statutory Auditors of the Company under Regulation 33 of the Listing Regulations are attached herewith as **Annexure- I**.

The Board Meeting commenced at 10:30 A.M and concluded at 01:30 P.M. (IST).

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral

Company Secretary & Compliance Officer

Encl.: As above

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM CONSOLIDATED FINANCIAL RESULTS****To The Board of Directors of Dr. Lal PathLabs Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended 30 September, 2023 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Deloitte
Haskins & Sells LLP**

6. The consolidated unaudited financial results includes the interim financial information/ financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total assets of Rs. 199 million as at 30 September, 2023, total revenues of Rs. 44 million and Rs. 85 million for the quarter and six months ended 30 September, 2023 respectively, total profit after tax of Rs. 4 million and Rs. 5 million for the quarter and six months ended 30 September, 2023 respectively, total comprehensive income of Rs. 4 million and Rs. 3 million for the quarter and six months ended 30 September, 2023 respectively and net cash outflows of Rs. 25 million for the six months ended 30 September, 2023 as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

For Deloitte Haskins & Sells LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal

Partner

(Membership No. 87104)

(UDIN: 23087104BGYLAY6891)

Place: Gurugram

Date: 2 November, 2023

Annexure A

List of entities consolidated

a) Parent Company: Dr. Lal PathLabs Limited


b) Subsidiaries held directly

| S. No. | Name of the Entity |
|---------------|--|
| 1 | Paliwal Diagnostics Private Limited |
| 2 | Paliwal Medicare Private Limited |
| 3 | Dr. Lal PathLabs Nepal Private Limited |
| 4 | Dr. Lal PathLabs Bangladesh Private Limited |
| 5 | Dr. Lal Ventures Private Limited |
| 6 | PathLabs Unifiers Private Limited |
| 7 | Dr. Lal PathLabs Kenya Private Limited |
| 8 | Suburban Diagnostics (India) Private Limited |

c) Subsidiaries held indirectly

| S. No. | Name of the Entity |
|---------------|-----------------------------------|
| 1 | Centrapath Labs Private Limited |
| 2 | APRL PathLabs Private Limited |
| 3 | Chanre Laboratory Private Limited |





Dr. Lal PathLabs Limited
CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana
Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and six months ended 30 September, 2023

(Rs. in million except as stated)

| Particulars | 3 months ended 30 September, 2023 | Preceding 3 months ended 30 June, 2023 | Corresponding 3 months ended in previous year 30 September, 2022 | Year to date figures for the current period ended 30 September, 2023 | Year to date figures for the previous period ended 30 September, 2022 | Previous year ended 31 March, 2023 |
|--|--------------------------------------|--|---|--|--|---------------------------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 Income | | | | | | |
| (a) Revenue from operations | 6,013 | 5,410 | 5,338 | 11,423 | 10,365 | 20,169 |
| (b) Other income | 181 | 144 | 87 | 325 | 170 | 417 |
| Total income | 6,194 | 5,554 | 5,425 | 11,748 | 10,535 | 20,586 |
| 2 Expenses | | | | | | |
| (a) Cost of materials consumed | 1,224 | 1,131 | 1,162 | 2,355 | 2,304 | 4,472 |
| (b) Employee benefits expense | 1,054 | 1,047 | 909 | 2,101 | 1,877 | 3,765 |
| (c) Finance costs | 78 | 80 | 109 | 158 | 194 | 375 |
| (d) Depreciation and amortisation expense | 359 | 351 | 388 | 710 | 747 | 1,502 |
| (e) Fees to collection centers/channel partners | 852 | 745 | 743 | 1,597 | 1,439 | 2,820 |
| (f) Other expenses | 1,105 | 1,025 | 1,086 | 2,130 | 2,132 | 4,213 |
| Total expenses | 4,672 | 4,379 | 4,397 | 9,051 | 8,693 | 17,147 |
| 3 Profit before tax | 1,522 | 1,175 | 1,028 | 2,697 | 1,842 | 3,439 |
| 4 Tax expense | | | | | | |
| (a) Current tax | 431 | 379 | 372 | 810 | 620 | 1,079 |
| (b) Deferred tax | (16) | (40) | (68) | (56) | (84) | (51) |
| Total tax expense | 415 | 339 | 304 | 754 | 536 | 1,028 |
| 5 Profit for the period (A) | 1,107 | 836 | 724 | 1,943 | 1,306 | 2,411 |
| 6 Other comprehensive income | | | | | | |
| Items that will not be reclassified to profit or loss | | | | | | |
| -Remeasurement of the defined benefit obligations | (2) | 6 | 38 | 4 | 33 | 26 |
| -Income tax in relation to the items that will not be reclassified to profit or loss | 1 | (2) | (9) | (1) | (8) | (6) |
| Items that may be reclassified to profit or loss | | | | | | |
| -Exchange differences on translation of foreign operations | - | (2) | - | (2) | (1) | (4) |
| Total other comprehensive income/ (loss) (B) | (1) | 2 | 29 | 1 | 24 | 16 |
| 7 Total comprehensive income (A+B) | 1,106 | 838 | 753 | 1,944 | 1,330 | 2,427 |
| Profit for the period attributable to: | | | | | | |
| Owners of the Company | 1,093 | 826 | 717 | 1,919 | 1,294 | 2,389 |
| Non-controlling interest | 14 | 10 | 7 | 24 | 12 | 22 |
| | 1,107 | 836 | 724 | 1,943 | 1,306 | 2,411 |
| Other comprehensive income for the period attributable to: | | | | | | |
| Owners of the Company | (1) | 2 | 28 | 1 | 24 | 16 |
| Non-controlling interest | - | - | 1 | - | - | - |
| | (1) | 2 | 29 | 1 | 24 | 16 |
| Total comprehensive income for the period attributable to: | | | | | | |
| Owners of the Company | 1,092 | 828 | 745 | 1,920 | 1,318 | 2,405 |
| Non-controlling interest | 14 | 10 | 8 | 24 | 12 | 22 |
| | 1,106 | 838 | 753 | 1,944 | 1,330 | 2,427 |
| 8 Paid-up equity share capital (Face value of Rs. 10 per share) | 835 | 834 | 834 | 835 | 834 | 834 |
| 9 Other equity | | | | | | 15,829 |
| 10 Earnings per share (Rs.) (Face value of Rs. 10 per share)(not annualised) | | | | | | |
| -Basic | 13.16 | 9.95 | 8.64 | 23.11 | 15.61 | 28.82 |
| -Diluted | 13.12 | 9.93 | 8.60 | 23.05 | 15.55 | 28.74 |

For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 2 November, 2023. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2023 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. During the quarter and six months ended 30 September 2023, the Parent Company has issued 11,000 and 52,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.

Further, during the quarter and six months ended 30 September 2023, the Parent Company has issued 49,975 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- v. The Board of Directors of the Parent Company had approved an Interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023.


The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- vi. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the Parent Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name APL Institute of Clinical Laboratory & Research Private Limited (APL) on 13 May, 2022 and 17 March, 2023 respectively.

The appointed date as per Scheme was 1 April, 2020. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company

Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the quarter and six months ended 30 September 2022, have been restated to give effect of the amalgamation.
- vii. The Board of Directors of the subsidiaries, Paliwal Medicare Private Limited (PMPL) and Paliwal Diagnostics Private Limited (PDPL) in their meetings held on 25 October, 2021 and 25 October, 2021 respectively had approved the "Scheme of Amalgamation" of PMPL with PDPL w.e.f 1 April, 2021, the appointed date. As per the said scheme, the undertaking of PMPL shall stand transferred to and vested in PDPL on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders of the respective companies, National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance Indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions.
- x. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'y) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 2 November, 2023


For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited
Statement of Consolidated Assets and Liabilities

(Rs. in millions except as stated)

| Particulars | As at | As at |
|--|--------------------|----------------|
| | 30 September, 2023 | 31 March, 2023 |
| | (Unaudited) | (Audited) |
| Assets | | |
| 1. Non-current assets | | |
| (a) Property, plant and equipment | 1,912 | 2,004 |
| (b) Capital work-in-progress | 98 | 30 |
| (c) Right-of-use assets | 1,558 | 2,006 |
| (d) Investment Property | 340 | |
| (e) Goodwill | 5,478 | 5,478 |
| (f) Other intangible assets | 3,292 | 3,562 |
| (g) Intangible assets under development | 13 | 20 |
| (h) Financial assets | | |
| (i) Loans | - | 1 |
| (ii) Other financial assets | 247 | 401 |
| (i) Non-current tax assets (net) | 206 | 205 |
| (j) Deferred tax assets (net) | 462 | 404 |
| (k) Other non-current assets | 59 | 14 |
| Total non-current assets | 13,665 | 14,125 |
| 2. Current assets | | |
| (a) Inventories | 409 | 338 |
| (b) Financial assets | | |
| (i) Investments | 1,104 | 1,499 |
| (ii) Trade receivables | 855 | 708 |
| (iii) Cash and cash equivalents | 1,200 | 2,637 |
| (iv) Bank balances other than (iii) above | 6,664 | 4,017 |
| (v) Loans | 12 | 14 |
| (vi) Other financial assets | 327 | 357 |
| (c) Other current assets | 217 | 160 |
| Total current assets | 10,788 | 9,730 |
| Total assets | 24,453 | 23,855 |
| Equity and liabilities | | |
| 1. Equity | | |
| (a) Equity share capital | 835 | 834 |
| (b) Other equity | 16,887 | 15,829 |
| Equity attributable to the owners of the Company | 17,722 | 16,663 |
| Non-controlling interest | 339 | 332 |
| Total equity | 18,061 | 16,995 |
| 2. Liabilities | | |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 417 | 833 |
| (ii) Lease liabilities | 1,236 | 1,300 |
| (b) Deferred tax liabilities (net) | 32 | 29 |
| Total non-current liabilities | 1,685 | 2,162 |
| Current liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 833 | 1,533 |
| (ii) Lease liabilities | 506 | 529 |
| (iii) Trade payables | | |
| Total outstanding dues of micro enterprises and small enterprises; and | 82 | 66 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,854 | 1,495 |
| Sub-total | 1,936 | 1,561 |
| (iii) Other financial liabilities | 480 | 463 |
| (b) Provisions | 333 | 291 |
| (c) Current tax liabilities (net) | 250 | 5 |
| (d) Other current liabilities | 369 | 316 |
| Total current liabilities | 4,707 | 4,698 |
| Total liabilities | 6,392 | 6,860 |
| Total equity and liabilities | 24,453 | 23,855 |

For Identification Only

Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited
Consolidated Cash Flow Statement

Annexure B

(Rs. in millions except as stated)

| Particulars | Year to date figures for the current period ednded 30 September, 2023 (Unaudited) | Year to date figures for the previous period ednded 30 September, 2022 (Unaudited) |
|---|---|--|
| Cash flows from operating activities | | |
| Profit for the year | 1,943 | 1,306 |
| Adjustments for : | | |
| Tax expense | 754 | 536 |
| Interest income | (245) | (145) |
| Gain on sale or fair valuation of investments | (55) | (16) |
| Surrender value of keyman insurance policy | (5) | (2) |
| Profit on disposal/discard of property, plant and equipment | (1) | (6) |
| Expense recognised in respect of employee share based compensation | 113 | 96 |
| Finance cost | 157 | 194 |
| Depreciation and amortisation expense | 710 | 747 |
| Provision for impairment of trade receivables and advances | 1 | 18 |
| Bad debts and advances written off (net) | 10 | 10 |
| Security deposits amortisation | - | 4 |
| Remeasurement of the defined benefit obligation | 4 | 33 |
| Exchange differences on translation of foreign operations | (2) | (1) |
| Operating profit before working capital changes | 3,384 | 2,774 |
| Adjustment for (increase)/decrease in operating assets: | | |
| (Increase) in inventories | (71) | (19) |
| (Increase) in trade receivables | (158) | (92) |
| Decrease in loans | 3 | - |
| Decrease in other financial assets | 20 | 12 |
| (Increase)/decrease in other assets | (61) | 41 |
| Adjustment for increase/(decrease) in operating liabilities: | | |
| Increase in trade payables | 375 | 217 |
| Increase in other financial liabilities | 32 | 100 |
| Increase/(decrease) in provisions | 42 | (13) |
| Increase/(decrease) in other liabilities | 53 | (59) |
| Cash generated from operations | 3,619 | 2,961 |
| Income taxes paid | (565) | (545) |
| Net cash generated by operating activities (a) | 3,054 | 2,416 |
| Cash flows from investing activities | | |
| Payments for purchase of property, plant and equipment | (252) | (273) |
| Proceeds from disposal of property, plant and equipment | 7 | 1 |
| Payments for purchase of other intangible assets | (25) | (18) |
| Interest received | 274 | 256 |
| Payments for business purchase on slump sale basis* | - | (11) |
| Net cash outflow for investment in subsidiaries | - | (164) |
| Payments for purchase of investments in mutual funds | (1,087) | (2,080) |
| Proceeds from sale of investments in mutual funds | 1,538 | 1,513 |
| Bank deposits placed with the banks | (7,030) | (7,797) |
| Bank deposits with banks encashed | 4,522 | 5,362 |
| Net cash used in investing activities (b) | (2,053) | (3,211) |
| Cash flows from financing activities | | |
| Proceeds from exercise of share options | 18 | 3 |
| Interest paid | (55) | (77) |
| Repayment of borrowings | (1,117) | (1,087) |
| Repayment of lease liability | (168) | (170) |
| Interest paid on lease liability | (103) | (117) |
| Dividend paid on equity shares | (1,013) | (1,030) |
| Net cash generated used in financing activities (c) | (2,438) | (2,478) |
| Net increase in cash and cash equivalents (a+b+c) | (1,437) | (3,273) |
| Cash and cash equivalents at the beginning of the year | 2,637 | 3,782 |
| Cash and cash equivalents at the end of the year | 1,200 | 509 |
| Components of cash and cash equivalents | | |
| Cash on hand | 12 | 13 |
| Balance with scheduled banks: | | |
| - on current accounts | 171 | 102 |
| - on cash credit accounts | 19 | 18 |
| - deposits with maturity of less than 3 months | 998 | 376 |
| Cash and cash equivalents in Cash Flow Statement | 1,200 | 509 |

*Value of assets and liabilities acquired on business purchase through slump sale have been included in movement of respective assets and liabilities


For Identification Only
A
S & Sells LLP

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited


1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and six months ended 30 September, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
(Partner)
(Membership No. 87104)
(UDIN: 23087104 BQYLAX 9699)

Place: Gurugram
Date: 2 November, 2023



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September, 2023

(Rs. in million except as stated)

| Particulars | 3 months ended 30 September, 2023 | Preceding 3 months ended 30 June, 2023 | Corresponding 3 months ended in previous 30 September, 2022 | Year to date figures for the current period ended 30 September, 2023 | Year to date figures for the previous period ended 30 September, 2022 | Previous year ended 31 March, 2023 |
|---|---|--|--|---|--|--|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 Income | | | | | | |
| (a) Revenue from operations | 5,317 | 4,801 | 4,681 | 10,118 | 9,086 | 17,690 |
| (b) Other income | 141 | 150 | 77 | 291 | 265 | 466 |
| Total income | 5,458 | 4,951 | 4,758 | 10,409 | 9,351 | 18,156 |
| 2 Expenses | | | | | | |
| (a) Cost of materials consumed | 1,043 | 990 | 1,024 | 2,033 | 2,024 | 3,896 |
| (b) Employee benefits expense | 901 | 898 | 760 | 1,799 | 1,569 | 3,155 |
| (c) Finance costs | 71 | 73 | 100 | 144 | 177 | 344 |
| (d) Depreciation and amortisation expense | 191 | 184 | 215 | 375 | 405 | 821 |
| (e) Fees to collection centers/channel partners | 808 | 706 | 701 | 1,514 | 1,362 | 2,665 |
| (f) Other expenses | 935 | 849 | 890 | 1,784 | 1,728 | 3,367 |
| Total expenses | 3,949 | 3,700 | 3,690 | 7,649 | 7,265 | 14,248 |
| 3 Profit before tax | 1,509 | 1,251 | 1,068 | 2,760 | 2,086 | 3,908 |
| 4 Tax expense | | | | | | |
| (a) Current tax | 398 | 359 | 342 | 757 | 575 | 1,014 |
| (b) Deferred tax | (19) | (44) | (63) | (63) | (75) | (30) |
| Total tax expense | 379 | 315 | 279 | 694 | 500 | 984 |
| 5 Profit for the period (A) | 1,130 | 936 | 789 | 2,066 | 1,586 | 2,924 |
| 6 Other comprehensive income | | | | | | |
| Items that will not be reclassified to profit or loss | | | | | | |
| -Remeasurement of the defined benefit obligations | (5) | 6 | 35 | 1 | 31 | 26 |
| -Income tax in relation to the items that will not be reclassified to profit or loss | 1 | (1) | (9) | - | (8) | (7) |
| Total other comprehensive income/(loss) (B) | (4) | 5 | 26 | 1 | 23 | 19 |
| 7 Total comprehensive income (A+B) | 1,126 | 941 | 815 | 2,067 | 1,609 | 2,943 |
| 8 Paid-up equity share capital (Face value of Rs. 10 per share) | 835 | 834 | 834 | 835 | 834 | 834 |
| 9 Other equity | | | | | | 16,065 |
| 10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised) | | | | | | |
| - Basic | 13.60 | 11.28 | 9.52 | 24.88 | 19.15 | 35.28 |
| - Diluted | 13.57 | 11.25 | 9.48 | 24.82 | 19.07 | 35.17 |

For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 2 November, 2023. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended 30 September, 2023 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. During the quarter and six months ended 30 September 2023, the Company has issued 11,000 and 52,000 equity shares of face value of Rs. 10 each respectively, on exercise of employee stock options.

Further, during the quarter and six months ended 30 September 2023, the Company has issued 49,975 equity shares of face value of Rs. 10 each, to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022").
- iv. The Board of Directors of the Company had approved an interim dividend of Rs. 6 per equity share (face value of INR 10 each) at their meeting held on 27 July, 2023 and this was paid on 23 August, 2023.


The Board of Directors of the Company had proposed final dividend of Rs. 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2023. The same was approved by the shareholders in the Annual General Meeting held on 12 September, 2023 and this was paid on 15 September, 2023.
- v. The Hon'ble New Delhi Bench and Hon'ble Ahmedabad Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') sanctioned the Scheme of Amalgamation ('Scheme') between the Company (Transferee Company) and its wholly owned subsidiary (Transferor Company) by the name APL Institute of Clinical Laboratory & Research Private Limiter (APL) on 13 May, 2022 and 17 March, 2023 respectively.

The appointed date as per Scheme was 1 April, 2020. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company

Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the 'pooling of interests' method in accordance with Ind AS 103 "Business Combinations" and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company.

Accordingly, the results for the quarter and six months ended 30 September 2022 have been restated to give effect of the amalgamation.
- vi. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- vii. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions.
- viii. Refer Annexure A for Statement of Standalone Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'y) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 2 November, 2023


For Identification Only
Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited
Statement of Standalone Assets and liabilities

(Rs. in millions except as stated)

| Particulars | As at | As at |
|--|--------------------|----------------|
| | 30 September, 2023 | 31 March, 2023 |
| | (Unaudited) | (Audited) |
| Assets | | |
| 1. Non-current assets | | |
| (a) Property, plant and equipment | 1,586 | 1,661 |
| (b) Capital work-in-progress | 97 | 30 |
| (c) Right-of-use assets | 1,373 | 1,791 |
| (d) Investment property | 340 | - |
| (e) Goodwill | 11 | 11 |
| (f) Other intangible assets | 143 | 152 |
| (g) Intangible assets under development | 13 | 20 |
| (h) Financial assets | | |
| (i) Investments | 10,720 | 10,720 |
| (ii) Loans | - | 1 |
| (iii) Other financial assets | 143 | 249 |
| (i) Non-current tax assets (net) | 153 | 130 |
| (j) Deferred tax assets (net) | 388 | 326 |
| (k) Other non-current assets | 36 | 10 |
| Total non-current assets | 15,003 | 15,101 |
| 2. Current assets | | |
| (a) Inventories | 323 | 233 |
| (b) Financial assets | | |
| (i) Investments | 932 | 1,414 |
| (ii) Trade receivables | 800 | 633 |
| (iii) Cash and cash equivalents | 894 | 2,203 |
| (iv) Bank balances other than (iii) above | 5,473 | 3,139 |
| (v) Loans | 10 | 12 |
| (vi) Other financial assets | 279 | 314 |
| (c) Other current assets | 206 | 153 |
| Total current assets | 8,917 | 8,101 |
| Total assets | 23,920 | 23,202 |
| Equity and liabilities | | |
| 1. Equity | | |
| (a) Equity share capital | 835 | 834 |
| (b) Other equity | 17,265 | 16,065 |
| Total equity | 18,100 | 16,899 |
| 2. Liabilities | | |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 417 | 833 |
| (ii) Lease liabilities | 1,103 | 1,148 |
| Total non-current liabilities | 1,520 | 1,981 |
| Current liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 833 | 1,533 |
| (ia) Lease liabilities | 424 | 440 |
| (ii) Trade payables | | |
| Total outstanding dues of micro enterprises and small enterprises | 78 | 61 |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,662 | 1,341 |
| sub-total | 1,740 | 1,402 |
| (iii) Other financial liabilities | 450 | 429 |
| (b) Provisions | 271 | 232 |
| (c) Current tax liabilities (net) | 249 | 5 |
| (d) Other current liabilities | 333 | 281 |
| Total current liabilities | 4,300 | 4,322 |
| Total liabilities | 5,820 | 6,303 |
| Total equity and liabilities | 23,920 | 23,202 |

For Identification Only

Deloitte Haskins & Sells LLP

Dr. Lal PathLabs Limited
Standalone Cash Flow Statement

(Rs. in millions except as stated)

| Particulars | Year to date figures for the current period ended 30 September, 2023 | Year to date figures for the previous period ended 30 September, 2022 |
|--|---|--|
| | (Unaudited) | (Unaudited) |
| Cash flows from operating activities | | |
| Profit for the period | 2,066 | 1,586 |
| Adjustments for : | | |
| Tax expense | 694 | 500 |
| Interest income | (200) | (122) |
| Dividend income from a subsidiary company | (32) | (120) |
| Gain on sale or fair valuation of investments | (48) | (8) |
| Surrender value of keyman insurance policy | (5) | (2) |
| Sundry balances written back | - | - |
| (Profit)/Loss on disposal / discard of property, plant and equipment | (1) | (12) |
| Expense recognised in respect of employee share based compensation | 110 | 89 |
| Finance cost | 144 | 177 |
| Depreciation and amortisation expense | 375 | 405 |
| Provision for impairment of trade receivables and advances | 1 | 3 |
| Bad debts and advances written off (net) | 1 | 6 |
| Security deposits amortisation | - | 4 |
| Remeasurement of the defined benefit obligation | 1 | 31 |
| Operating profit before working capital and other changes | 3,106 | 2,537 |
| Changes in working capital: | | |
| Adjustment for (increase)/decrease in operating assets: | | |
| (Increase) in inventories | (90) | (15) |
| (Increase) in trade receivables | (169) | (66) |
| Decrease in loans | 3 | - |
| (Increase) in other financial assets | 14 | (1) |
| (Increase)/decrease in other assets | (53) | 36 |
| Adjustment for increase/(decrease) in operating liabilities: | | |
| Increase in trade payables | 339 | 265 |
| Increase in other financial liabilities | 31 | 96 |
| Increase/(decrease) in provisions | 39 | (6) |
| Increase/(decrease) in other liabilities | 52 | (39) |
| Cash generated from operations | 3,272 | 2,807 |
| Income taxes paid | (535) | (497) |
| Net cash generated from operating activities (a) | 2,737 | 2,310 |
| Cash flows from investing activities | | |
| Payments for purchase of property, plant and equipment | (213) | (245) |
| Proceeds from disposal of property, plant and equipment | 3 | 1 |
| Payments for purchase of other intangible assets | (16) | (11) |
| Dividend received from a subsidiary company | 32 | 120 |
| Interest received | 235 | 247 |
| Investment in subsidiaries | - | (218) |
| Payments for purchase of investments in mutual funds | (838) | (1,945) |
| Proceeds from sale of investments in mutual funds | 1,368 | 995 |
| Bank deposits placed with the banks | (6,134) | (7,292) |
| Bank deposits with banks encashed | 3,897 | 5,157 |
| Net cash used in investing activities (b) | (1,666) | (3,191) |
| Cash flows from financing activities | | |
| Proceeds from exercise of share options | 18 | 3 |
| Repayment of borrowings | (1,117) | (1,085) |
| Repayment of lease liability | (141) | (142) |
| Interest paid on lease liability | (89) | (100) |
| Interest paid | (55) | (77) |
| Dividend paid on equity shares | (996) | (994) |
| Net cash generated used in financing activities (c) | (2,380) | (2,395) |
| Net increase/ decrease in cash and cash equivalents (a+b+c) | (1,309) | (3,276) |
| Cash and cash equivalents at the beginning of the year | 2,203 | 3,513 |
| Cash and cash equivalents at the end of the period/year | 894 | 237 |
| Components of cash and cash equivalents | | |
| Cash on hand | 9 | 11 |
| Balance with scheduled banks: | | |
| - on current accounts | 74 | 38 |
| - on cash credit accounts | 19 | 18 |
| - deposits with maturity of less than 3 months | 792 | 170 |
| Total cash and cash equivalents in Cash Flow Statement | 894 | 237 |